Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.39 |
| ▸ | SCN1A | P35498 | 2/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.39 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.38 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.38 |
| ▸ | CCR3 | P51677 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 3/20 | 0.37 |
| ▸ | HTR1F | P30939 | 3/20 | 0.37 |
| ▸ | HTR1B | P28222 | 2/20 | 0.37 |
| ▸ | HTR1D | P28221 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HCN1 | O60741 | 2/20 | 0.36 |
| ▸ | HCN4 | Q9Y3Q4 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20147577 | 0.86 | RET (0.41) | RETP2RX7CCR3KMT2AHCN1 | |
| SCHEMBL21652024 | 0.81 | P2RX7 (0.57) | P2RX7SCN1ASCN2ASCN3AKMT2A | |
| SCHEMBL20068945 | 0.80 | HCN1 (0.51) | CCR3KMT2AGAAHCN1 | |
| SCHEMBL20069742 | 0.80 | KMT2A (0.54) | P2RX7KMT2AHCN1HCN4 | |
| SCHEMBL20068951 | 0.78 | SCN1A (0.45) | RETP2RX7SCN1ASCN2ASCN3A | |
| SCHEMBL20068935 | 0.77 | BCAT2 (0.50) | RETP2RX7SCN1ASCN2ASCN3A | |
| SCHEMBL20068936 | 0.77 | HCN1 (0.55) | HCN1HCN4 | |
| SCHEMBL20069770 | 0.76 | LMNA (0.50) | RETCCR3LMNAGAA | |
| SCHEMBL20068937 | 0.76 | RET (0.45) | RETP2RX7SCN1ASCN2ASCN3A | |
| SCHEMBL16565618 | 0.76 | ATM (0.49) | P2RX7SCN1ASCN2ASCN3AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | RET 1/4885P2RX7 1456/4885SCN1A 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.